Clinical research is the process by which new drugs, devices, and medical procedures are tested in people to determine whether they are safe and effective. It spans everything from the first cautious dose given to a handful of volunteers through to post-market surveillance of millions of patients, and it is the primary reason modern medicine can distinguish treatments that work from those that don’t. The system is elaborate, expensive, and imperfect, but understanding how it operates helps make sense of why a drug reaches your pharmacy shelf and what the evidence behind it actually means.
How a Drug Moves From Lab to Patient
Clinical trials are organized into phases, each with a distinct purpose. Phase 1 trials are small, typically involving a few dozen volunteers, and focus on finding a safe dose range and identifying side effects. The classic approach escalates the dose step by step, watching for toxicity at each level. Rule-based methods for doing this, like the traditional 3+3 design, have been widely used for decades but tend to treat a meaningful number of participants at doses too low to be effective. Newer model-based and model-assisted designs are more accurate at finding the right dose.
The picture has also gotten more complicated with newer drug classes. Targeted therapies and immunotherapies often don’t cause the kind of dose-dependent toxicity that older chemotherapy drugs do. Their side effects can be chronic, unpredictable, and unrelated to the amount of drug given, which means simply escalating until someone gets sick is a poor strategy. Researchers increasingly look at how the drug behaves in the body and what it does to its molecular target, rather than relying solely on toxicity, to pick the right dose.
Phase 2 trials expand to a larger group, often a few hundred people, and start looking at whether the treatment actually works against the disease. Phase 3 trials are bigger still, frequently involving thousands of participants across multiple hospitals and countries, and are designed to confirm effectiveness and monitor side effects at scale. One interesting wrinkle: treatment effects measured in Phase 2 don’t always hold up in Phase 3. In Crohn’s disease trials, for example, rates of clinical remission and response have been higher in Phase 2 than Phase 3 studies, a pattern that may reflect tighter patient selection or the smaller, more controlled environments of earlier trials.
Phase 4 begins after a drug reaches the market. No matter how many patients are studied before approval, the true safety profile of a drug only emerges through ongoing surveillance once it’s being used by a much wider, more diverse population in real-world conditions. Post-marketing surveillance systems collect reports of adverse events and can detect rare side effects that pre-approval trials were simply too small to catch.
Designing Trials to Get Honest Answers
The randomized controlled trial remains the benchmark for evaluating treatments. By randomly assigning participants to receive either the experimental treatment or a comparison (often a placebo or standard therapy), researchers ensure the groups are comparable in every way except the treatment itself. This eliminates the confounding variables that plague other study types. Blinding adds another layer of protection: when neither the participants nor the researchers know who is getting what, unconscious biases in reporting symptoms or assessing outcomes are kept in check.
That said, randomized trials are not the only way to get reliable evidence, and observational studies sometimes come closer to their results than critics assume. A landmark analysis comparing observational studies with randomized trials across a range of treatments found that in most cases, the estimates of treatment effects were similar. Only two out of nineteen comparisons showed the observational results falling outside the confidence range of the randomized trial results.
Not every trial asks whether a new drug is better than what already exists. When an effective treatment is already available, assigning patients to a placebo can be unethical. In these situations, noninferiority trials are used: they test whether a new treatment is at least as good as the current standard, even if it’s not demonstrably better. A new drug might be slightly less effective but far easier to take, cheaper, or associated with fewer side effects, and a noninferiority design can establish that the trade-off is acceptable. These trials are harder to design and interpret than straightforward head-to-head comparisons, though, and how to set the acceptable margin of “not worse” is an ongoing area of debate.
Adaptive trial designs represent another shift. Instead of locking every detail of the trial in stone before it starts, adaptive designs allow pre-planned modifications based on accumulating data. A trial might drop a dose arm that clearly isn’t working, shift more patients into a promising treatment group, or adjust the sample size. These designs can be more efficient, more informative, and more ethical than rigid fixed designs, because they make better use of time and participants.
The Psychology of Being in a Trial
When someone enrolls in a clinical trial, psychological and behavioral changes kick in that have nothing to do with the drug being tested. The most famous of these is the placebo effect. Far from being “all in someone’s head,” placebos trigger measurable changes in brain chemistry. Research has shown that neurotransmitter systems involved in pain relief and reward, including opioid and dopamine pathways, are activated following placebo administration. Brain regions including the anterior cingulate cortex and prefrontal cortex light up on imaging. A patient’s expectation of improvement can influence outcomes as much as some active treatments, and the effect tends to be larger for novel interventions and procedures.
The flip side is the nocebo effect, where negative expectations produce real harm. If a participant in a trial is told a drug might cause headaches, they’re more likely to report headaches even if they received a sugar pill. Nocebo effects are a meaningful cause of dropout from clinical trials and non-adherence to medication in routine care. The informed consent process itself, which by law must disclose potential side effects, can inadvertently plant the expectation of harm and amplify nocebo responses. The effect leads to more frequent adverse event reports, higher dropout rates, and skewed assessments of how well a treatment actually works. Managing this tension between ethical transparency and the risk of suggestion is one of the trickier problems in trial design.
Then there’s the Hawthorne effect: people behave differently simply because they know they’re being observed. A recent analysis of a blood pressure trial estimated that participants who were already taking blood pressure medication experienced an average immediate drop of about 4 mmHg in systolic blood pressure upon enrolling, likely because being in a study made them more diligent about taking their existing pills. That effect had nothing to do with the intervention being tested. Recruitment into a trial, along with the social interaction and monitoring that come with it, can shift baseline conditions enough to complicate the interpretation of results.
Who Gets Studied and Who Gets Left Out
Clinical trials have a well-documented diversity problem. A large cohort study of over 20,000 U.S.-based trials found that only 43% reported any race or ethnicity data at all. Among those that did, the median enrollment was about 80% White, 10% Black, 6% Hispanic or Latino, and 1% Asian. Combined minority enrollment was consistently below census estimates. Industry-funded and academic trials were less likely than government-funded trials to report race and ethnicity data, and industry funding was also associated with a lower proportion of minority participants.
This matters because drugs can behave differently across populations. Genetic variation influences how people metabolize medications, and social determinants of health affect disease presentation and treatment response. If a drug is tested overwhelmingly in one demographic group, the confidence that it will work the same way in everyone else is weaker than it should be.
Barriers to participation for minority patients are well recognized but hard to dismantle. Historical abuses in medical research have created lasting distrust, and logistical factors like distance to trial sites, inflexible work schedules, and lack of insurance compound the problem. One intervention that shows promise is investigator diversity. A survey experiment found that Black respondents reported substantially higher interest in participating in a study led by a race-concordant investigator, roughly a 13% increase. The effect was driven primarily by perceived trustworthiness, suggesting that representation among the people running trials, not just those enrolled in them, can shift participation patterns.
Children represent another underserved group. Pediatric physiology differs from adult physiology in ways that affect how drugs are absorbed, distributed, and cleared, which means adult dosing data can’t simply be scaled down. Yet running pharmacokinetic trials in children is complicated by limits on blood sample volumes and concerns about pain from repeated blood draws. Population-based modeling approaches can help by spreading the data burden across more participants so that each child provides fewer samples.
Ethics and Oversight
Every clinical trial involving human participants must be reviewed and approved by an institutional review board, or IRB. The IRB is a federally mandated group whose job is to protect the rights and welfare of research participants. It reviews the study design, the risks and potential benefits, and the informed consent documents before a single volunteer can be enrolled. At some institutions, the IRB also evaluates the scientific quality of the proposed research, acting as a second set of eyes on methodology.
The modern ethics framework didn’t appear out of nowhere. It grew out of a series of historical documents responding to serious abuses: the Nuremberg Code following Nazi experiments, the Declaration of Helsinki issued by the World Medical Association, the Belmont Report in the United States, and federal regulations collectively known as the Common Rule. Each built on the last, establishing principles like voluntary informed consent, the right to withdraw at any time, and the requirement that risks to participants be minimized and justified by expected benefits.
Informed consent is the cornerstone of ethical research, but measuring whether participants actually understand what they’ve agreed to is surprisingly difficult. A systematic review of tools designed to assess consent comprehension found wide variability, with only three instruments demonstrating strong enough measurement properties to be considered high quality. The gap between signing a consent form and genuinely understanding the trial’s risks, procedures, and alternatives remains one of the field’s persistent challenges.
Compassionate use, sometimes called expanded access, creates its own ethical tension. When a patient with a serious illness has no approved options left, regulatory pathways allow them to receive an experimental drug outside of a clinical trial. The logic is humane, but it can complicate future research: if large numbers of patients access a drug through compassionate use, it drains the supply available for formal trials and reduces the pool of patients willing to be randomly assigned to a placebo arm. Studying a drug’s true effectiveness becomes much harder when no one wants to risk getting the inactive comparator.
Publication Bias and the Push for Transparency
For decades, the results of clinical trials were selectively reported. Trials with positive outcomes were more likely to be published, and published without misleading interpretations, than trials with negative or ambiguous results. This created a skewed evidence base where treatments looked better on paper than they actually were. The passage of the FDA Amendments Act in 2007 (FDAAA) required registration and results reporting for many trials, and the effect was dramatic. Before the law, 64% of trials supporting neuropsychiatric drug approvals were registered and only 10% reported results; afterward, both figures reached 100%. Before the law, positive trials were about 50% more likely to be published than non-positive ones. After, positive and non-positive trials were published at the same rate.
The improvement is real but incomplete. Registration requirements apply mainly to trials of FDA-regulated products, and enforcement has been uneven. Selective outcome reporting, where researchers highlight favorable endpoints while downplaying others, remains a concern. Still, the shift toward mandatory transparency has substantially reduced the most overt forms of publication bias, giving clinicians and patients a more honest view of what the evidence actually shows.
Real-World Evidence and Decentralized Trials
Traditional clinical trials take place at specialized research centers, with strict enrollment criteria and frequent in-person visits. This model produces high-quality data but also creates significant access barriers. Decentralized clinical trials aim to loosen those constraints by using remote digital technologies, telemedicine, local labs, and community providers to bring the trial to the participant rather than the other way around. The approach can broaden participation geographically and demographically, which is especially relevant for people who live far from academic medical centers or can’t take time off work for frequent clinic visits.
Meanwhile, regulators are increasingly willing to consider real-world evidence drawn from sources like electronic health records, insurance claims databases, and disease registries. An analysis of new drug and biologics approvals by the U.S. FDA found that 116 approvals incorporated real-world evidence in some form, with the proportion increasing each year. Among those, 65 of the real-world evidence studies influenced the FDA’s final approval decision. In Europe, a similar trend is emerging: about 9% of European Medicines Agency reports reviewed in a recent study incorporated real-world evidence, drawing on registries, electronic health records, and claims databases.
Real-world evidence is not a replacement for controlled trials. Observational data from health records and registries can be biased in ways that are hard to detect and adjust for. But it fills gaps that trials can’t, especially for rare diseases where enrolling enough patients for a traditional trial is impractical, for long-term safety questions that extend beyond a trial’s follow-up period, and for understanding how a treatment performs outside the tightly controlled conditions of a study protocol.
Artificial Intelligence in Trial Operations
One of the most resource-intensive parts of running a trial is finding the right participants and the right locations. Matching patients to trials they’re eligible for traditionally involves manual review of medical records against long lists of inclusion and exclusion criteria, a slow and error-prone process. AI-driven tools are starting to automate parts of this work. A proof-of-concept system using natural language processing was developed to match cancer patients with Phase 1 oncology trials by analyzing medical records for cancer type, performance status, genetic mutations, and measurable disease, then generating a summary score with explanations for why each match was or wasn’t appropriate.
On the site-selection side, choosing which hospitals and clinicians should participate in a trial is often done through personal networks and past relationships, which can perpetuate the same demographic imbalances the field is trying to fix. A deep learning framework called DocTr was designed to optimize this process by integrating patient encounter data, trial documents, and historical enrollment records. Tested on nearly 25,000 clinicians and over 5,000 trials, it achieved substantially higher match accuracy than existing methods. An optimization layer improved fairness scores related to patient race and ethnicity by up to 25% compared with real-world enrollment patterns, while also minimizing scheduling conflicts between competing trials.
These tools are still in early stages, and their real-world impact will depend on whether they can be integrated into the messy, fragmented infrastructure that clinical research actually runs on. But the potential is clear: faster enrollment, broader representation, and fewer trials that fail simply because they couldn’t find enough participants in time. The bottleneck in getting new treatments to patients has never been purely scientific. It has always been partly logistical, and that’s the gap AI is best positioned to narrow.